{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/BSX/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://creativecommons.org/publicdomain/zero/1.0/","generated_at":"2026-08-18T00:52:37.186Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8451,"canonical_name":"BOSTON SCIENTIFIC CORP","cik":"0000885725","uei":null,"lei":null,"duns":null,"ticker":"BSX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":16,"fda":28,"clinical":49,"court":1,"open":1},"count":95,"timeline":[{"ts":"2026-07-01","kind":"sec.insider.f","reporter":"Monson Jonathan","title":"EVP and CFO","shares":1010,"price_per_share":43.06,"usd_value":43491,"security_title":"Common Stock","importance":15.0434906},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Monson Jonathan","title":"EVP and CFO","shares":2087,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"Rapid Refill Continuous Injection System, UPN M00566001","excerpt":"Devices contain recalled Medline Namic Angiographic Control Syringe with Rotating Adaptor. There is a risk of syringe loosening or disconnecting from the manifold, resulting in loose connection or complete disconnection. May lead to difficulty connecting syringe, inability to aspirate or inject properly, fluid leakage, or separation of the syringe from the system, potentially requiring device exchange and prolonging the procedure.","accession_number":"Z-2725-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-24","kind":"sec.filing","form_type":"11-K","title":"11-K — BOSTON SCIENTIFIC CORP — 2026-06-24","url_slug":"/sec/cik-0000885725/11-k/0000885725-26-000046","accession_number":"0000885725-26-000046","importance":30},{"ts":"2026-06-19","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"Boston Scientific TheraSphere 360 Y-90 Management Platform, Model Number M00139509001; Radiological Image Processing System.","excerpt":"Software anomaly occurs when a user adds one or more vials to the cart and subsequently returns to the Activity Calculator to modify one or more input. When a user modifies an input and selects \"Recalculate\",  the dose calculation is updated correctly; however, any vials that were previously added to the cart are not automatically updated to reflect the revised calculation.","accession_number":"Z-2771-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21M402, IFU Reference Number LBL1062","excerpt":"Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.","accession_number":"Z-2755-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M401; Percutaneous Cardiac Ablation Catheter","excerpt":"Boston Scientific is replacing specific FARASTAR PFA generators which have a configuration that is not compatible for use with the FARAPOINT PFA catheter.","accession_number":"Z-2753-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M401; Percutaneous Cardiac Ablation Catheter","excerpt":"Labeling discrepancy:  Devices distributed with Instructions For Use (IFU) did not include  FARAPOINT PFA catheter information.","accession_number":"Z-2750-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARASTAR Pulsed Field Ablation Generator, Product ID M004PFCE61M401; Percutaneous Cardiac Ablation Catheter","excerpt":"Labeling discrepancy:  Devices distributed with Instructions For Use (IFU) did not include  FARAPOINT PFA catheter information.","accession_number":"Z-2751-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARASTAR PFA Generator, Product ID M004PFCE61M460; Percutaneous Cardiac Ablation Catheter","excerpt":"Labeling discrepancy:  Devices distributed with Instructions For Use (IFU) did not include  FARAPOINT PFA catheter information.","accession_number":"Z-2752-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARADRIVE STEERABLE SHEATH CLEAR OUS, used to facilitate access to the vasculature and into the chambers of the heart, Material Number M004PFCE21M402, IFU Reference Number 51659727-01","excerpt":"Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.","accession_number":"Z-2757-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARADRIVE Steerable Sheath Clear IDE, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21C602, IFU Reference Number 51636751-01","excerpt":"Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.","accession_number":"Z-2754-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-06-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"FARADRIVE STEERABLE SHEATH (CLEAR) - US, used to facilitate access to the vasculature and into the chambers of the heart, Material Number M004PF21M402, IFU Reference Number 51654495-01","excerpt":"Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.","accession_number":"Z-2756-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-28","kind":"sec.insider.g","reporter":"Mahoney Michael F","title":"Chairman, President & CEO","shares":386755,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 12-15mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2629-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 10-12mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2628-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 15-18mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2630-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 6-8mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2626-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 8-10mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2633-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 12-15mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2635-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 15-18mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2636-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 6-8mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2632-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 18-20mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2637-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 8-10mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2627-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Wireguided 10-12mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2634-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"CRE Pro Wireguided 18-20mm 240cm","excerpt":"Potential sterile breach of the pouches in which devices are packaged.","accession_number":"Z-2631-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — Habiger David C — 2026-05-21","url_slug":"/sec/cik-0001326409/4/0001225208-26-005546","accession_number":"0001225208-26-005546","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"SD","title":"SD — BOSTON SCIENTIFIC CORP — 2026-05-21","url_slug":"/sec/cik-0000885725/sd/0000885725-26-000043","accession_number":"0000885725-26-000043","importance":30},{"ts":"2026-05-20","kind":"sec.insider.p","reporter":"LUDWIG EDWARD J","title":null,"shares":3580,"price_per_share":56.68,"usd_value":202914,"security_title":"Common Stock","importance":50.2029144},{"ts":"2026-05-20","kind":"sec.insider.p","reporter":"Habiger David C","title":null,"shares":2250,"price_per_share":55.9195,"usd_value":125819,"security_title":"Common Stock","importance":50.125818875},{"ts":"2026-05-20","kind":"sec.insider.p","reporter":"Pegus Cheryl","title":null,"shares":1770,"price_per_share":56.49,"usd_value":99987,"security_title":"Common Stock","importance":50.0999873},{"ts":"2026-05-19","kind":"sec.insider.p","reporter":"Habiger David C","title":null,"shares":2200,"price_per_share":56.9451,"usd_value":125279,"security_title":"Common Stock","importance":50.12527922},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — BOSTON SCIENTIFIC CORP — 2026-05-18","url_slug":"/sec/cik-0000885725/8-k/0000885725-26-000041","accession_number":"0000885725-26-000041","importance":35},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — BOSTON SCIENTIFIC CORP — 2026-05-18","url_slug":"/sec/cik-0000885725/8-k/0000885725-26-000042","accession_number":"0000885725-26-000042","importance":35},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain","security_title":null,"status":"RECRUITING","accession_number":"NCT06827262","excerpt":"[\"Chronic Low-back Pain\",\"Vertebrogenic Pain Syndrome\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"SIMPLAAFY Clinical Trial","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06521463","excerpt":"[\"Atrial Fibrillation\",\"Stroke\",\"Bleeding\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07502599","excerpt":"[\"Orthostatic Hypotension\",\"Reflex Syncope\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia","security_title":null,"status":"RECRUITING","accession_number":"NCT06686485","excerpt":"[\"Concomitant Procedures\",\"Atrial Fibrillation\",\"PFA\",\"LAAC\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A DirEct to PatieNt Study in Chronic Pain","security_title":null,"status":"COMPLETED","accession_number":"NCT05515341","excerpt":"[\"Chronic Pain\"]","importance":25},{"ts":"2026-05-12","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"Orca Single Use Air/Water and Suction Valves, Material Number (UPN) SUV-617-50; The Orca Air/Water Valve is intended to be used to control the air/water function on an endoscope during a GI (gastrointestinal) endoscopic procedure.","excerpt":"Boston Scientific is initiating a medical device removal of  Orca Sterile, Single Use Air/Water and Suction Valves due to a higher than anticipated occurrence of the suction button sticking.","accession_number":"Z-2413-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"IT Matters: The Erectile Restoration Registry","security_title":null,"status":"ENROLLING_BY_INVITATION","accession_number":"NCT04200937","excerpt":"[\"Erectile Dysfunction\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04905069","excerpt":"[\"Prostate Cancer\"]","importance":25},{"ts":"2026-05-11","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"Intera Oncology INTERA 3000 Hepatic Artery Infusion Pump, AP-0300H, implantable drug delivery device","excerpt":"There is the potential for leakage along the drug pathway from the pump through the end of the catheter.","accession_number":"Z-2580-2026","status":"Completed","product_type":"device","importance":60},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04058990","excerpt":"[\"Coronary Artery Disease\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"OPTION-EMEA Clinical Trial","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07349121","excerpt":"[\"Atrial Fibrillation (AF)\",\"Stroke Prevention in Patients With Atrial Fibrillation\",\"Left Atrial Appendage Closure\",\"Pulsed Field Ablation\",\"Atrial Fibrillation Ablation Procedure\",\"Concomitant Procedures\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Prospective, Multi-center Study to Evaluate Efficacy and Safety of BSJ020R in Treatment of AVF for Hemodialysis (RANGER AV Japan Study)","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06639451","excerpt":"[\"Arteriovenous Fistula Stenosis\",\"Arteriovenous Fistula\",\"Vascular Access\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Paresthesia-Free Fast-Acting Subperception (FAST) Study","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04618471","excerpt":"[\"Chronic Pain\"]","importance":25},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)","security_title":null,"status":"RECRUITING","accession_number":"NCT04032470","excerpt":"[\"Essential Tremor\"]","importance":25},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions","security_title":"NA","status":"RECRUITING","accession_number":"NCT06959524","excerpt":"[\"Coronary Arterial Disease (CAD)\",\"de Novo Lesions in Native Coronary Arteries\"]","importance":25},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area","security_title":"NA","status":"RECRUITING","accession_number":"NCT07035431","excerpt":"[\"Anastomotic Leaks\",\"Hartmanns Stump Leakage\"]","importance":25},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"LUDWIG EDWARD J","title":null,"shares":3800,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"Habiger David C","title":null,"shares":3800,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"Zane Ellen M","title":null,"shares":3800,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"WICHMANN DAVID S","title":null,"shares":3800,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE","security_title":"NA","status":"SUSPENDED","accession_number":"NCT06174805","excerpt":"Sponsor Decision","importance":80},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Patient Retrospective Outcomes (PRO)","security_title":null,"status":"RECRUITING","accession_number":"NCT01550575","excerpt":"[\"Chronic Pain\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System","security_title":"NA","status":"RECRUITING","accession_number":"NCT07444320","excerpt":"[\"Paroxysmal Atrial Fibrillation\",\"Persistent Atrial Fibrillation\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07353710","excerpt":"[\"Atrial Arrhythmia\",\"Intracardiac Echocardiography\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure","security_title":"NA","status":"RECRUITING","accession_number":"NCT07069738","excerpt":"[\"Heart Failure - NYHA II - IV\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation","security_title":"NA","status":"RECRUITING","accession_number":"NCT07187115","excerpt":"[\"Atrial Fibrillation (AF)\",\"Persistant Atrial Fibrillation\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System","security_title":"NA","status":"RECRUITING","accession_number":"NCT06735534","excerpt":"[\"Persistent Atrial Fibrillation\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","security_title":"PHASE4","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04790370","excerpt":"[\"Pulmonary Embolism\"]","importance":25},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)","security_title":null,"status":"RECRUITING","accession_number":"NCT03053141","excerpt":"[\"Cardiac Arrythmias\"]","importance":25},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Feasibility Study of the FARAFLEX Mapping and PFA System","security_title":"NA","status":"RECRUITING","accession_number":"NCT06510556","excerpt":"[\"Atrial Fibrillation\",\"Persistent Atrial Fibrillation\",\"Paroxysmal AF\"]","importance":25},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)","security_title":"NA","status":"RECRUITING","accession_number":"NCT07106970","excerpt":"[\"Persistent Atrial Fibrillation\"]","importance":25},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT06819865","excerpt":"[\"Acute Pulmonary Embolism\"]","importance":25},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05063565","excerpt":"[\"Hepatocellular Carcinoma\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05303467","excerpt":"[\"Glioblastoma Multiforme\",\"Recurrent Glioblastoma\"]","importance":30},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06192758","excerpt":"[\"Prostate\",\"Cancer\"]","importance":25},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"BoStOn SCientific Rhythm MAnagemenT REgiStry (SOCRATES)","security_title":null,"status":"RECRUITING","accession_number":"NCT04823663","excerpt":"[\"Cardiac Disease\"]","importance":25},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT01385176","excerpt":"[\"Heart Failure\",\"Congestive Heart Failure\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04647253","excerpt":"[\"In-Stent Restenosis\"]","importance":60},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06492174","excerpt":"[\"In-Stent Restenosis\"]","importance":60},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"FARAPULSE™ Pulsed Field Ablation System","security_title":null,"status":"RECRUITING","accession_number":"NCT06762717","excerpt":"[\"Paroxysmal AF\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07195708","excerpt":"[\"Weight Loss\"]","importance":25},{"ts":"2026-04-23","kind":"court.docket","reporter":"mad","title":"Feder v. Mahoney <font color=\"red\"><b>DO NOT DOCKET IN THIS CASE - ALL FILINGS ARE TO BE MADE IN LEAD CASE 26-CV-11296-JEK</font></b>","security_title":"850 Securities/Commodities","excerpt":"15:78m(a) Securities Exchange Act","accession_number":"1:26-cv-11864","product_type":"Julia E. Kobick","importance":45},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Intra-operative Pancreatoscopy in Patients With IPMN","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03729453","excerpt":"[\"Intraductal Papillary Mucinous Neoplasm\"]","importance":25},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Hot AXIOS™ for Bile Duct Drainage in Malignant Stenosis","security_title":"NA","status":"SUSPENDED","accession_number":"NCT06750146","excerpt":"Sponsor decision","importance":80},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"RESCUE: Discontinuation of GLP-1","security_title":null,"status":"RECRUITING","accession_number":"NCT07190794","excerpt":"[\"Obesity\"]","importance":25},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Radiofrequency (RF) Ablation Prospective Outcomes Study","security_title":null,"status":"COMPLETED","accession_number":"NCT04673032","excerpt":"[\"Pain, Chronic\"]","importance":25},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06808217","excerpt":"[\"Atrial Fibrillation\",\"Pulsed Field Ablation\",\"FARAPULSE\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07458243","excerpt":"[\"Carotid Artery Stenosis\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Combined CM and STN Stimulation for Motor Epilepsy","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07458217","excerpt":"[\"Motor Epilepsy\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation","security_title":"NA","status":"COMPLETED","accession_number":"NCT02928497","excerpt":"[\"Stroke\"]","importance":25},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"MANDARIN (S6371)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05016245","excerpt":"[\"Inoperable Hepatocellular Carcinoma\"]","importance":60},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"PROMUS PREMIER™ China Post-Approval Study","security_title":null,"status":"COMPLETED","accession_number":"NCT03273023","excerpt":"[\"Coronary Artery Disease\"]","importance":25},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries","security_title":null,"status":"COMPLETED","accession_number":"NCT03037411","excerpt":"[\"Arterial Occlusive Diseases\",\"Atherosclerosis\",\"Vascular Diseases\",\"Arteriosclerosis\"]","importance":25},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06096337","excerpt":"[\"Persistent Atrial Fibrillation\"]","importance":25},{"ts":"2026-03-30","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"LUX-DX II, Arrythmia detector and alarm, Model M302, with SERVER SW LATITUDE DRAGON US, Model 6460, Version 7.5","excerpt":"For some patients upgraded from a LUX-Dx M301 device to a new Model M302 or M312, the new ICM device is not collecting PVC Burden data (both M302/M312) or monitoring for Bradyarrhythmia and Pause (M312 only). In addition, for these devices that are not being monitored, the LATITUDE Clarity programming screens have discrepant information, indicating that the monitoring is enabled for these features in one location and not enabled in another location.","accession_number":"Z-2048-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-03-30","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class II","security_title":"LUX-Dx II Plus, Arrythmia detector and alarm, Model M312, with SERVER SW LATITUDE DRAGON EU (Europe), Model 6446, Version 7.5, or SERVER SW LATITUDE DRAGON AU (Australia/New Zealand), Model 6448, Version 7.5","excerpt":"For some patients upgraded from a LUX-Dx M301 device to a new Model M302 or M312, the new ICM device is not collecting PVC Burden data (both M302/M312) or monitoring for Bradyarrhythmia and Pause (M312 only). In addition, for these devices that are not being monitored, the LATITUDE Clarity programming screens have discrepant information, indicating that the monitoring is enabled for these features in one location and not enabled in another location.","accession_number":"Z-2049-2026","status":"Ongoing","product_type":"device","importance":60},{"ts":"2026-03-19","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class I","security_title":"Boston Scientific Cardiac Resynchronization Therapy (CRT)labeled as:    1. VALITUDE CRT-P EL, Model Number U125;   2. VALITUDE CRT-P EL MRI, Model Number U128;   3. VISIONIST CRT-P EL, Model Number U225;   4. VISIONIST CRT-P EL, Model Number U226;   5. VISIONIST CRT-P EL MRI, Model Number U228.","excerpt":"Updated software, Brady software maintenance release 6 (SMR6), is now available for the ACCOLADE\" family of pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps)1 and the advisory population is expanding to include all CRT-P and dual-chamber extended life (DR-EL) devices.    Dual chamber modes are specifically indicated for treatment of the following:    \" Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block    \" VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm    \" Low cardiac output or congestive heart failure secondary to bradycardia","accession_number":"Z-1771-2026","status":"Ongoing","product_type":"device","importance":100},{"ts":"2026-03-19","kind":"fda.recall","reporter":"Boston Scientific Corporation","title":"Class I","security_title":"Boston Scientific Pacemaker, Implantable Pulse Generator, Pacemaker (non- Cardiac Re-Synchronization Therapy) labeled as:    1. ESSENTIO SR SL, Model Number L100;   2. ESSENTIO DR SL Pacemaker, Model Number L101;   3. ESSENTIO SR SL MRI Pacemaker, Model Number L110;   4. ESSENTIO DR SL MRI Pacemaker, Model Number L111;   5. ESSENTIO DR EL Pacemaker, Model Number L121;   6. ESSENTIO DR EL MRI Pacemaker, Model Number L131;   7. PROPONENT SR SL Pacemaker, Model Number L200;   8. PROPONENT DR SL Pacemaker, Model Number L201;   9. PROPONENT DR (VDD) SL Pacemaker, Model Number L209;   10. PROPONENT SR SL Pacemaker, Model Number L210;   11. PROPONENT DR SL MRI Pacemaker, Model Number L211;   12. PROPONENT DR EL Pacemaker, Model Number L221;   13. PROPONENT DR EL MRI Pacemaker, Model Number L231*;   14. ACCOLADE SR SL Pacemaker, Model Number L300;   15. ACCOLADE DR SL Pacemaker, Model Number L301;   16. ACCOLADE SR SL MRI Pacemaker, Model Number L310;   17. ACCOLADE DR SL MRI Pacemaker, Model ","excerpt":"Updated software, Brady software maintenance release 6 (SMR6), is now available for the ACCOLADE\" family of pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps)1 and the advisory population is expanding to include all CRT-P and dual-chamber extended life (DR-EL) devices.    Dual chamber modes are specifically indicated for treatment of the following:    \" Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block    \" VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm    \" Low cardiac output or congestive heart failure secondary to bradycardia","accession_number":"Z-1770-2026","status":"Ongoing","product_type":"device","importance":100},{"ts":"2026-03-17","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05501873","excerpt":"[\"Atrial Fibrillation\"]","importance":25},{"ts":"2026-03-02","kind":"clinical.trial","reporter":"Boston Scientific Corporation","title":"ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study","security_title":null,"status":"COMPLETED","accession_number":"NCT06526546","excerpt":"[\"Paroxysmal Atrial Fibrillation\"]","importance":25},{"ts":"2024-12-31","kind":"open.payments","reporter":"Boston Scientific Corporation","title":"$49002919.0 to 68994 physicians (2024–2024)","security_title":"manufacturer","excerpt":"WATCHMAN Access System","accession_number":"2024","usd_value":49002919,"importance":70}]}